Bet Inhibitor Gsk525762 Uses, Dosage, Side Effects and more
Bet Inhibitor Gsk525762 is under investigation in clinical trial NCT01943851 (A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies).
| Trade Name | Bet Inhibitor Gsk525762 |
| Generic | Molibresib |
| Molibresib Other Names | Bet inhibitor gsk525762, Molibresib |
| Type | |
| Formula | C22H22ClN5O2 |
| Weight | Average: 423.9 Monoisotopic: 423.1462027 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
